Metabolic Inflexibility with Obesity and the Effects of Fenofibrate on Skeletal Muscle Fatty Acid Oxidation
- Resource Type
- Authors
- Chantal Underkofler; Kristen E. Boyle; Neda Rasouli; Joseph A. Houmard; Jacob E. Friedman; Rachel C. Janssen
- Source
- Hormone and Metabolic Research. 49:50-57
- Subject
- Adult
Male
0301 basic medicine
medicine.medical_specialty
Adolescent
Endocrinology, Diabetes and Metabolism
Clinical Biochemistry
Mitochondrion
Biology
Biochemistry
Article
Prediabetic State
Young Adult
03 medical and health sciences
Endocrinology
Insulin resistance
Fenofibrate
Internal medicine
medicine
Humans
Obesity
Prediabetes
Muscle, Skeletal
Beta oxidation
Cells, Cultured
Aged
chemistry.chemical_classification
Fatty Acids
Biochemistry (medical)
Fatty acid
Skeletal muscle
General Medicine
Middle Aged
Lipid Metabolism
medicine.disease
030104 developmental biology
medicine.anatomical_structure
chemistry
Female
Oxidation-Reduction
medicine.drug
- Language
- ISSN
- 1439-4286
0018-5043
This study was designed to investigate mechanisms of lipid metabolic inflexibility in human obesity and the ability of fenofibrate (FENO) to increase skeletal muscle fatty acid oxidation (FAO) in primary human skeletal muscle cell cultures (HSkMC) exhibiting metabolic inflexibility. HSkMC from 10 lean and 10 obese, insulin resistant subjects were treated with excess fatty acid for 24 hours (24hFA) to gauge lipid-related metabolic flexibility. Metabolically inflexible HSkMC from obese individuals were then treated with 24hFA in combination with FENO to determine effectiveness for increasing FAO. Mitochondrial enzyme activity and FAO were measured in skeletal muscle from subjects with pre-diabetes (n=11) before and after 10 weeks of fenofibrate in vivo. 24hFA increased FAO to a greater extent in HSkMC from lean vs. obese subjects (+49% vs. +9%, for lean vs. obese, respectively; p